Plain-English translation of NCT04496479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called , which involves transplanting healthy liver cells into lymph nodes in your abdomen. Researchers believe these cells may help your liver function better if you have end-stage liver disease. The study will enroll up to 12 people and test different amounts of the transplanted cells to see which dose is safest and most effective.
End-stage liver disease is a serious condition with limited treatment options besides a full liver transplant, which many people cannot access due to organ shortages. This study explores whether transplanting liver cells into a different location in the body might offer patients a new hope for improving liver function without needing a whole-organ transplant.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a transplant of liver cells injected into lymph nodes near your small intestine. The study is designed as a 'dose escalation' trial, meaning early participants receive a smaller amount of cells and later participants may receive larger amounts, depending on safety results. You will have regular follow-up visits to check your health, liver function, and how well the transplanted cells are working.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
LyGenesis, Inc.
Enrollment target
~12 participants
Started
March 2022
Primary completion
August 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paulo Fontes, MD
LyGenesis, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.